Neoadjuvant Therapy

Neoadjuvant therapy is treatment given before the main intervention, usually surgery, to shrink a tumor, lower its stage, and improve the chance of a complete removal. In cancers linked to asbestos, this most often means chemotherapy, immunotherapy, radiation, or a combination given in the weeks or months before an operation.

Origin

The word combines the Greek-derived prefix 'neo-' (new) with 'adjuvant,' from the Latin 'adjuvare' (to help). It entered oncology vocabulary in the early 1980s to distinguish treatment given before surgery from 'adjuvant' treatment given afterward, as evidence grew that early systemic therapy could downstage tumors and improve surgical outcomes.

Significance in Asbestos Context

Neoadjuvant therapy is central to the modern treatment of pleural mesothelioma and some asbestos-related lung cancers, because these tumors spread along surfaces and are hard to remove completely. The most common pre-surgical regimen has been cisplatin (or carboplatin) combined with pemetrexed, given before extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). More recently, neoadjuvant immunotherapy with checkpoint inhibitors such as nivolumab and ipilimumab has been used in clinical trials and, in some centers, in standard care.

For patients, the neoadjuvant phase is often the most physically demanding part of treatment. Side effects (nausea, fatigue, low blood counts, infections, kidney effects, and hospitalizations) are real injuries that document the severity of the disease. The treatment record (drugs, doses, cycles, imaging response, complications) also becomes important evidence: it confirms the diagnosis and stage, supports damages in a lawsuit, and is required documentation for many asbestos bankruptcy trust claims. If surgery cannot ultimately be performed because the disease progressed or the patient's condition declined, the neoadjuvant treatment course still reflects significant harm.

Example Sentence

After her pleural mesothelioma was staged, the tumor board recommended neoadjuvant cisplatin and pemetrexed chemotherapy before considering pleurectomy/decortication surgery.

Related Terms

Adjuvant Therapy, Chemotherapy, Immunotherapy, Mesothelioma, Pleurectomy/Decortication (P/D), Extrapleural Pneumonectomy (EPP), Tumor Staging

Notes

• Keep a treatment log: dates of each cycle, drug names and doses, side effects, hospitalizations, and missed work. This information supports both your medical care and any legal or trust claims.
• Ask your oncologist whether your regimen follows NCCN (National Comprehensive Cancer Network) guidelines for mesothelioma or lung cancer, and request copies of imaging reports before and after neoadjuvant treatment. These show how the tumor responded.
• Discuss expected toxicities and supportive care (anti-nausea drugs, kidney protection, blood count monitoring) before starting, and ask whether a clinical trial of neoadjuvant immunotherapy is appropriate for your case.
• If you are considered for surgery, ask the surgeon specifically how response to neoadjuvant therapy will be measured and what findings would change the surgical plan.
• Talk with an asbestos attorney early in treatment. Statutes of limitations vary by state, and preserving employment, product-identification, and medical records during the neoadjuvant phase is far easier than reconstructing them later.